Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.7.3507

Silencing of Lysyl Oxidase Gene Expression by RNA Interference Suppresses Metastasis of Breast Cancer  

Liu, Jian-Lun (Department of Breast Surgery, Cancer Hospital, Guangxi Medical University)
Wei, Wei (Department of Breast Surgery, Cancer Hospital, Guangxi Medical University)
Tang, Wei (Department of Breast Surgery, Cancer Hospital, Guangxi Medical University)
Jiang, Yi (Department of Breast Surgery, Cancer Hospital, Guangxi Medical University)
Yang, Hua-Wei (Department of Breast Surgery, Cancer Hospital, Guangxi Medical University)
Li, Jing-Tao (Department of Breast Surgery, Cancer Hospital, Guangxi Medical University)
Zhou, Xiao (Department of Breast Surgery, Cancer Hospital, Guangxi Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.7, 2012 , pp. 3507-3511 More about this Journal
Abstract
Objective: The aim of this study was to investigate possible mechanisms of LOX gene effects on invasion and metastasis of breast cancer cells by RNA interference. Methods: LOX-RNAi-LV was designed, synthesized, and then transfected into a breast cancer cell line (MDA-MB-231). Expression of LOX, MMP-2 and MMP-9 was determined by real-time PCR, and protein expression of LOX by Western blotting. Cell migration and invasiveness were assessed with Transwell chambers. A total of 111 cases of breast cancer tissues, cancer-adjacent normal breast tissues, and 20 cases of benign lesion tissues were assessed by immunohistochemistry. Results: Expression of LOX mRNA and protein was suppressed, and the expression of MMP-2 and MMP-9 was significantly lower in the RNAi group than the control group (P<0.05), after LOX-RNAi-LV was transfection into MDA-MB-231 cells. Migration and invasion abilities were obviously inhibited. The expression of LOX protein in breast cancer, cancer-adjacent normal breast tissues and benign breast tumor were 48.6% (54/111), 26.1% (29/111), 20.0% (4/20), respectively, associations being noted with clinical stage, lymph node metastasis, tumor size and ER, PR, HER2, but not age. LOX protein was positively correlated with MMP-2 and MMP-9. Conclusion: LOX displayed an important role in invasion and metastasis of breast cancer by regulating MMP-2 and MMP-9 expression which probably exerted synergistic effects on the extracellular matrix (ECM).
Keywords
Breast cancer; lysyl oxidase; RNA interference (RNAi); metastasis; matrix metalloproteinases;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Payne SL, Angela R. Hess AR, et al (2005). Lysyl oxidase facilitates intracellular signaling in invasive breast cancer cells. Proc Amer Assoc Cancer Res, 46, 67-8.
2 Peyrol S, Raccurt M, Gerard F, et al (1997). Lysy1 oxidase gene expression in the stromal reaction to in situ and invasive ductal breast carcinoma. Am J Pathol, 150, 497-507.
3 Sulaiman S, Shahril MR, Shaharudin SH, et al (2011). Fat intake and its relationship with pre- and postmenopausal breast cancer risk: a case-control study in Malaysia. Asian Pac J Cancer Prev, 12, 2167-78.
4 Talvensaari MA, Paakko P, Turpeenniemi HT (2003). Matrix metalloproteinase-2 (MMP-2) is associated with sunixal in breast carcinoma. Br J Cancer, 89, 1270-5.   DOI   ScienceOn
5 Woznick AR, Braddock AL, Dulai M, et al (2005). Lysyl oxidase expression in bronchogenic carcinoma. Am J surg, 189, 297-301.   DOI
6 Yu Q, Stamenkovic I (2000). Cell surface-localized matrixmetalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes, 14, 163-76.
7 Zucker S, Hymowitz M, Rollo EE, et al (2001). Tumorigenic potential of extracellar matrix metalloproteinase inducer. Am J Pathol, 158, 1921-8.   DOI
8 Akiri G, Sabo E, Dafni H, et al (2003). Lysyl oxidase-related protein-1 promotes tumorfibrosis and tumor progression in vivo. Cancer Res, 63, 1657-66.
9 Erler JT, Bennewith KL, Nicolau M, et al (2006). Lysyl oxidase is essential for hypoxia-induced metastasis. Nature, 440, 1222-6.   DOI
10 Erler JT, Giaccia AJ (2006). Lysyl oxidase mediates hypoxic control of metastasis. Cancer Res, 66, 10238-41.   DOI
11 Fong SF, Dietzsch E, Fong KS, et al (2007). Lysyl oxidase-like 2 expression is increased in colon and esophageal tumors and asociated with lass differentiated colon turners. Genes Chromosomes Cancer, 46, 644-55.   DOI
12 Hafez MM, Hassan ZK, Zekri AR, et al (2012). MicroRNAs and metastasis-related gene expression in Egyptian breast cancer patients. Asian Pac J Cancer Prev, 13, 591-8.   과학기술학회마을   DOI
13 Kirschmann DA, Seftor EA, Fong SF, et al (2002). A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res, 62, 4478-83.
14 Holtmeier C, Gorogh T, Beier U, et al (2003). Overexpression of a novel lysyl oxidase-like gene in human head and neck squamous cell carcinomas. Anticancer Res, 23, 2585-91.
15 Jing DC, Blidaru A, Condrea I, et al (2006). MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med, 10, 499-510.   DOI
16 Kirschmann DA, Payne SL, Seftor EA , et al (2005). Tumor suppressor gene Maspin and hypoxia inversely regulate lysyl oxidase facilitated breast cancer motility. Proc Amer Assoc Cancer Res, 46, 57-8.
17 Lhotak S, Elavathil LJ, Vukmirovic-Popovic, et al (2000). Immunolocalization of matrix- metallo-proteinases and their inhibitors in clinical specimens of bone metastasis from breast carcinoma. Clin Exp Metastasis, 18, 463-70.   DOI
18 Liotta LA, Steeg PA, Stetler-stevenson WG (1991). Canaer metastasis and angiogensis: and imbalance of positive negative regulation. Cell, 64, 327-31.   DOI   ScienceOn
19 Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) Method. Methods, 25, 402-8.   DOI   ScienceOn
20 Loh SY, Chew SL, Lee SY (2011). Physical Activity and Women with Breast Cancer: Insights from Expert Patients. Asian Pac J Cancer Prev, 12, 87-94.
21 Nakopoulou L, Katsarou S, Giannopoulou I, et al (2002). Correlation of tissue inhibitor of metalloproteinase- 2 with proliferative actixity and patients sunal in breast cancer. Mod Patho1, 15, 26-34.   DOI